Skip to main content
search
 
 

FDA Awards Breakthrough Device Status to DPP® Syphilis TnT

Learn More
 
 

FDA Awards Breakthrough Device Status to the SURE CHECK® HIV Self-Test

Learn More
1
1

Announcing the receipt of CLIA Waiver for DPP HIV-Syphilis. Contact your local Chembio Representative for more information

DPP® HIV-Syphilis

CLIA Waved Badge

Upcoming Events:

National Conference on Correctional Health Care 2025, Booth #315

November 1-5, 2025
Baltimore, MD

Stay up to date with our latest news.

Uncategorized

FDA AWARDS BREAKTHROUGH DEVICE STATUS TO THE DPP® SYPHILIS TnT ASSAY

FOOD AND DRUG ADMINISTRATION AWARDS BREAKTHROUGH DEVICE STATUS TO THE DPP® SYPHILIS TnT ASSAY  Medford,…
Chembio

FDA Awards Breakthrough Device Status to the SURE CHECK® HIV Self-Test

Medford N.Y USA/Strasbourg France – June 17, 2025 – Chembio Diagnostic Systems, Inc., a subsidiary…
Chembio

Chembio Diagnostics Inc. receives a grant for Development of a DPP Congenital Syphilis Assay

Chembio Diagnostics Inc., a subsidiary of Biosynex, receives a grant  for Development of a DPP…
About Us

We enable longer and healthier living through detection and monitoring of infectious diseases at the point of care.

Our mission is to be a leader in the development, manufacturing and commercialization of diagnostic solutions. We are dedicated to delivering exceptional point-of-care products that are easy to use, fast and accurate.

Our Core Values: “RAPID”

Relentless

Accountable

Passionate

Innovative

Diverse

Learn More

We are looking for talented, dedicated people wishing to contribute to our common vision of enhancing the health and well being of people worldwide.

Subscribe to the Chembio Mailing List